Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Carl Zeiss SMS GmbH, a subsidiary of Carl-Zeiss-Stiftung, is a German company. The firm provides solutions for mask making and lithography.

Sagem Télécommunications SA, a subsidiary of Safran SA, is a company headquartered in Paris, France, that engages in manufacturing communication equipment.

Archer-Daniels-Midland Co. engages in the production of oilseeds, corn, wheat, cocoa, and other agricultural commodities. It operates through the following segments: Ag Services and Oilseeds, Carbohydrate Solutions, Nutrition, Other, and Corporate. The Ag Services and Oilseeds segment includes activities related to the origination, merchandising, crushing, and further processing of oilseeds, such as soybeans, and soft seeds, such as cottonseed, sunflower seed, canola, rapeseed, and flaxseed, into vegetable oils and protein meals. The Carbohydrate Solutions segment consists of corn and wheat wet and dry milling and other activities. The Nutrition segment serves various end markets including food, beverages, nutritional supplements, and feed and premix for livestock, aquaculture, and pet food. The Corporate segment represents results of early-stage start-up companies within ADM Ventures. The company founded in 1902 and is headquartered in Chicago, IL.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment offers solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights (MSR) valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Carl Zeiss AG (German: [kaʁl tsaɪs]), branded as ZEISS, is a German manufacturer of optical systems and optoelectronics, founded in Jena, Germany in 1846 by optician Carl Zeiss. Together with Ernst Abbe (joined 1866) and Otto Schott (joined 1884) he laid the foundation for today's multi-national company. The current company emerged from a reunification of Carl Zeiss companies in East and West Germany with a consolidation phase in the 1990s. ZEISS is active in four business segments with approximately equal revenue, Industrial Quality and Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology in almost 50 countries, has 30 production sites and around 25 development sites worldwide.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Baxter AG, part of Baxter International, Inc., is a company headquartered in Volketswell, Switzerland. The firm wholesales pharmaceutical products.

Gekko specialises in the design, manufacturing and installation of modular low-height plants as well as optimisation of systems by delivering low-energy flowsheets. With offices in Australia, Canada and South Africa, Gekko has successful manufactured and installed over 500 units across 43 countries worldwide to recover sulfides, free gold, native copper, silver and gems. The company was established in year 1996.

CITIC Dicastal Co., Ltd. manufactures aluminum alloy wheels including thousands of casting, casting & spining, and forged wheels. It serves the North America, Europe, and Japan Markets. The company was founded in 1988 and is headquartered in Qin Huangdao, China

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.

Distributes construction supplies

AMADA Co., Ltd. engages in the manufacture, sale, leasing, repair, maintenance, checking, and inspection of metal working machinery and tools. It operates through the following business divisions: Sheet Metal Fabrication Machine, Metal Cutting Machine, Machine Tools, Stamping Press, Precision Welding Machine and Others. The Sheet Metal Fabrication Machine division offers integrated solutions from machines through control software, peripheral devices and consumables to maintenance service. The Metal Cutting Machine division provides steel frames for high-rise buildings, bridges and other structures. The Machine Tools division provides the precision finishing of medical devices and other equipment. The Stamping Press division engages in the sale of stamping presses. The Precision Welding Machine division provides precision welding and processing solutions for automotive electrical equipment, secondary batteries, household electrical appliances, LCD (Liquid Crystal Display) displays, personal computers, medical devices, and numerous other products. The Others segment includes real estate and automobile leasing, and golf course management services. The company was founded by Isamu Amada on September 10, 1946 and is headquartered in Isehara, Japan.

Tianjin Huiwang Technology Co., Ltd., established on 2015-12-17, Business scope includes new energy technology development;Electromechanical processing;Production and sales of machinery and equipment;Wujinjiaodian,rubber products,plastic products(Except for ultra-thin plastic bags),wooden product,wood,Labor protection supplies,Wholesale and retail of electronic products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

China Aviation Development Guizhou Liyang Aviation Power Co., Ltd., established on 1997-11-07, Business scope includes legal,regulations,Those prohibited by the State Council's decision shall not operate;law,regulations,The State Council has decided to allow(approval)of,After approval by the examination and approval authority(approval)file management;law,regulations,The State Council has decided that a license is not required(approval)of,Market entities independently choose to operate.(Research and development of aero-engines and their derivatives,manufacture,test,Sales,repair,Serve;mold,knives,fixture,Measuring tool design,manufacture,Sales,repair;Heat treatment,Metrology detection,Non-destructive testing,Physical and chemical testing;network,computer,software integration,communication,Research and development of energy and power products,Manufacturing and sales;technology development,technology transfer,Technical Services,technical consulting;self-operated,Agent products and technologies and required equipment,software,Parts,Import and export business of raw and auxiliary materials.)